Effective treatments for patients with metastatic castration-resistant prostate cancer following
disease progression on enzalutamide are currently an unmet clinical need. Simultaneous …

VNLG‐152 is a novel retinamide (NR) shown to suppress growth and progression of
genetically diverse prostate cancer cells via inhibition of androgen receptor signaling and …

Background Despite the clinical efficacy of enzalutamide monotherapy in patients with
advanced prostate cancer, therapeutic resistance and disease progression are inevitable …

Enzalutamide is a potent second-generation androgen receptor (AR) antagonist with activity
in metastatic castrate-resistant prostate cancer (CRPC). Although enzalutamide is initially …

Clinical management of castration-resistant prostate cancer (CRPC) resulting from
androgen deprivation therapy remains challenging. CRPC is driven by aberrant activation of …

Niclosamide effectively downregulates androgen receptor variants (AR-Vs) for treating
enzalutamide and abiraterone-resistant prostate cancer. However, the poor pharmaceutical …

Background The progression of castration‐resistant prostate cancer (CRPC) still relies on
the function of androgen receptor (AR), achieved by evolving mechanisms to reactivate AR …

Background Enzalutamide, a next-generation antiandrogen agent, is approved for the
treatment of metastatic castration-resistant prostate cancer (CRPC). While enzalutamide has …

Abstract The phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway is a
key pathway activated in castrate-resistant prostate cancer (CRPC). This preclinical study …

Management of castration-resistant prostate cancer (CRPC) is challenging due to lack of
efficacious therapy. Luteinizing hormone-releasing hormone (LHRH) analogs appear to act …